QDEL vs. NEOG, CLDX, NTLA, MYGN, LNTH, SMMT, HIMS, JANX, INDV, and CERT
Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Lantheus (LNTH), Summit Therapeutics (SMMT), Hims & Hers Health (HIMS), Janux Therapeutics (JANX), Indivior (INDV), and Certara (CERT). These companies are all part of the "medical" sector.
Neogen (NASDAQ:NEOG) and QuidelOrtho (NASDAQ:QDEL) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.
In the previous week, QuidelOrtho had 14 more articles in the media than Neogen. MarketBeat recorded 20 mentions for QuidelOrtho and 6 mentions for Neogen. QuidelOrtho's average media sentiment score of 0.28 beat Neogen's score of 0.09 indicating that Neogen is being referred to more favorably in the media.
QuidelOrtho has higher revenue and earnings than Neogen. QuidelOrtho is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
QuidelOrtho received 109 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 67.23% of users gave QuidelOrtho an outperform vote while only 57.19% of users gave Neogen an outperform vote.
96.7% of Neogen shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 0.7% of Neogen shares are owned by company insiders. Comparatively, 1.0% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Neogen has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.
Neogen currently has a consensus target price of $22.50, suggesting a potential upside of 85.34%. QuidelOrtho has a consensus target price of $61.60, suggesting a potential upside of 55.40%. Given QuidelOrtho's stronger consensus rating and higher possible upside, equities research analysts plainly believe Neogen is more favorable than QuidelOrtho.
Neogen has a net margin of 0.17% compared to Neogen's net margin of -0.34%. Neogen's return on equity of 5.54% beat QuidelOrtho's return on equity.
Summary
QuidelOrtho beats Neogen on 10 of the 18 factors compared between the two stocks.
Get QuidelOrtho News Delivered to You Automatically
Sign up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
QuidelOrtho Competitors List
Related Companies and Tools
